Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kala Pharmaceuticals (NASDAQ: KALA) announced its participation in two virtual healthcare investor conferences in August 2021. On August 11, COO Todd Bazemore will discuss next-generation ophthalmology treatments, focusing on dry eye and AMD at the Wedbush PacGrow Healthcare Virtual Conference. On August 17, a pre-recorded presentation will be available, followed by a panel featuring CMO Kim Brazzell discussing emerging therapeutics for dry eye disease. Access to the events can be found on the Kala website.
Details
News Market Reaction – KALA
The recorded move for KALA in the trading session of this news was -2.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in August.
2021 Wedbush PacGrow Healthcare Virtual Conference
Date: Wednesday, August 11, 2021
Todd Bazemore, Chief Operating Officer, will participate in a panel discussion titled, “Goldeneye: Next-generation ophthalmology treatments with a focus on dry eye, more potent pan-VEGF inhibition and less invasive dosing for wet AMD,” at 9:45 a.m. ET.
H.C. Wainwright Opthalmology Virtual Conference
Date: Tuesday, August 17, 2021
A pre-recorded presentation will be made available beginning Tuesday, August 17, 2021 at 7:00 a.m. ET. Additionally, Kim Brazzell, Ph.D., Chief Medical Officer, will participate in a panel discussion titled, “Emerging Therapeutics for Dry Eye Disease,” at 2:00 p.m. ET.
To access a webcast and subsequent archived recording of the H.C. Wainwright podium presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension)
Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.